Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib, Dostarlimab and Radiotherapy in Metastatic TNBC
NCT04837209Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2021
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Started Jul 2021; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04837209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837209.